Immuno-Oncology | Specialty

Immunotherapy Research Key to Moving SCLC Field Forward

October 23rd 2018

Ramsey N. Asmar, MD, discusses recent advances and next steps in small cell lung cancer.

Neoadjuvant Nivolumab Plus Ipilimumab Active in dMMR Early-Stage Colon Cancer

October 23rd 2018

First results from a study of neoadjuvant ipilimumab plus nivolumab in patients with early-stage colon cancer found a major pathologic response achieved in all 7 patients with mismatch repair deficient tumors.

FDA Extends Review Period for Frontline Nivolumab/Ipilimumab in TMB-High NSCLC

October 22nd 2018

The FDA has added 3 months to the review period for the combination of nivolumab plus low-dose ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.

Engineered Anti-MAGE-A T-Cells Show Early Promise

October 21st 2018

Genetically engineered T-cells targeting a common tumor antigen appeared safe and demonstrated some evidence of antitumor activity in a first-in-human clinical evaluation.

Dr. Rosenberg on Dosing of Nivolumab Plus Ipilimumab in Bladder Cancer

October 20th 2018

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses dosing for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with metastatic urothelial carcinoma at the 2018 ESMO Congress.

Pembrolizumab/Axitinib Improves Survival in Frontline RCC

October 19th 2018

Combining the PD-1 inhibitor pembrolizumab with the VEGF inhibitor axitinib significantly improved survival versus sunitinib as a first-line treatment for patients with advanced or metastatic renal cell carcinoma.

Testing Reveals Extent of Lynch Syndrome

October 16th 2018

The presence of Lynch syndrome correlates with microsatellite-instability status and DNA mismatch-repair deficiency across a variety of tumor types.

Combinations With RT May Improve Immunotherapy Response

October 16th 2018

One potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.

The Importance of Curiosity in Expanding Cancer Immunology

October 13th 2018

Jill O'Donnell-Tormey, PhD, chief executive officer, director of scientific affairs, Cancer Research Institute, discusses the importance of curiosity in expanding the role of immunology in the treatment of cancer.

Dr. Sharma Discusses Immune Checkpoint Resistance in GU Cancers

October 12th 2018

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.

Nivolumab Misses OS Endpoint in SCLC Study

October 12th 2018

Single-agent nivolumab (Opdivo) did not improve overall survival compared with standard topotecan or amrubicin, where approved, in patients with small cell lung cancer who relapsed following platinum-based chemotherapy.

Lead Investigator Discusses Frontline Pembrolizumab in NSCLC

October 12th 2018

Gilberto Lopes, MD, discusses the KEYNOTE-042 results and ongoing developments with immunotherapy in NSCLC.

Immunotherapy in NSCLC: Audience Q&A

October 10th 2018

I-O Therapy Versus Surgery or Chemotherapy in NSCLC

October 10th 2018

PD-L1 Expression in NSCLC

October 10th 2018

Managing Pneumonitis in NSCLC

October 10th 2018

Immunotherapy in Locally Advanced NSCLC

October 10th 2018

Experience With I-O Therapies in Second-Line NSCLC

October 10th 2018

Continuing/Re-Challenging With I-O Therapy in NSCLC

October 10th 2018

Treating Relapsed/Refractory NSCLC After I-O Therapy

October 10th 2018